Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Shibuya-ku
-
Tokyo, Shibuya-ku, Japan, 150-0002
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HNC or undefined histology (not otherwise specified [NOS]) HNC diagnosis from 01-Jan-2013 to 30-Sep-2016 using Japanese disease code
- Age 18 years or older at initial diagnosis of HNC regardless of staging
Exclusion Criteria:
- Diagnosis of another malignancy on or before the initial diagnosis of HNC with the exception of non-melanoma skin cancer and metastatic cancer
- Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HNC patients
HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016. |
Non-Interventional
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients receiving radiotherapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving surgery as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving chemotherapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving targeted therapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving supportive care as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Distribution of Treatment History in Head and Neck Cancer (HNC) patients
Time Frame: Approximately 45 months
|
Approximately 45 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distribution of overall survival (OS) by age
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by gender
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by stage
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by tumor site
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by treatment regimen
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Number of treatment-limiting adverse events (AEs)
Time Frame: Approximately 45 months
|
Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies
|
Approximately 45 months
|
|
Number of withdrawals due to AEs
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC
Time Frame: At Baseline
|
At Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA209-868
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.